Cullinan Therapeutics (CGEM) News Today $7.35 -0.07 (-0.94%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$7.34 0.00 (-0.07%) As of 07/8/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Buy" from Brokerages1 hour ago | marketbeat.comCGEM - Cullinan Therapeutics Inc Dividends - MorningstarJuly 2, 2025 | morningstar.comMAssenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)June 21, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by BrokeragesJune 14, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Coverage Initiated at Stifel NicolausJune 11, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 4.7% - Time to Sell?June 5, 2025 | marketbeat.comCullinan Therapeutics Nabs Licensing Rights to Myeloma TreatmentJune 4, 2025 | marketwatch.comCullinan Therapeutics in-pact with Genrix Bio for velinotamigJune 4, 2025 | msn.comCullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune DiseasesJune 4, 2025 | globenewswire.comBank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)June 4, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short InterestJune 2, 2025 | marketbeat.comTaiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJune 1, 2025 | prnewswire.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 9.2% - Here's WhyMay 30, 2025 | marketbeat.comCullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWoodline Partners LP Makes New $2.04 Million Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 27, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Millennium Management LLCMay 26, 2025 | marketbeat.comAmeriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 26, 2025 | marketbeat.comCullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025May 22, 2025 | globenewswire.com115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial MarketsMay 22, 2025 | marketbeat.comPatient Square Capital LP Has $10.71 Million Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 16, 2025 | marketbeat.comCullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Position Raised by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 15, 2025 | marketbeat.comUBS Group Cuts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $24.00May 14, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 295,467 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 11, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 10, 2025 | marketbeat.comCullinan Therapeutics reports Q1 EPS (74c), consensus (81c)May 9, 2025 | msn.comCullinan Therapeutics: Q1 Earnings SnapshotMay 8, 2025 | sfgate.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comBoxer Capital Management LLC Invests $11.06 Million in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)May 4, 2025 | marketbeat.comQ1 EPS Forecast for Cullinan Therapeutics Raised by AnalystMay 3, 2025 | marketbeat.comCullinan Therapeutics to begin US trial of CLN-978 to treat Sjögren’s diseaseApril 30, 2025 | msn.com634,558 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Bought by Foresite Capital Management VI LLCApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $12.55 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 30, 2025 | marketbeat.comLynx1 Capital Management LP Buys 846,965 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 29, 2025 | marketbeat.comCullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United StatesApril 29, 2025 | globenewswire.comRenaissance Technologies LLC Sells 91,292 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 28, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from BrokeragesApril 28, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Blue Owl Capital Holdings LPApril 26, 2025 | marketbeat.comJPMorgan Chase & Co. Buys 169,104 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 26, 2025 | marketbeat.comMarshall Wace LLP Sells 402,071 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 25, 2025 | marketbeat.comJump Financial LLC Has $806,000 Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 24, 2025 | marketbeat.comCullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025April 23, 2025 | globenewswire.comVoss Capital LP Makes New Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 23, 2025 | marketbeat.com43,399 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by XTX Topco LtdApril 22, 2025 | marketbeat.comWalleye Capital LLC Decreases Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)April 21, 2025 | marketbeat.comCullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in ...April 18, 2025 | seekingalpha.comCullinan Therapeutics' (CGEM) Buy Rating Reiterated at HC WainwrightApril 18, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Hyperfine (HYPR) and Cullinan Management (CGEM)April 17, 2025 | markets.businessinsider.comCullinan receives approval from EMA to initiate Phase 1 trial of CLN-978April 17, 2025 | markets.businessinsider.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.000.57▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼13▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADPT News SPRY News CNTA News TARS News BEAM News SRPT News ARQT News IMCR News SDGR News EVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEM Stock Alerts